These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17882911)

  • 1. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study.
    Penn R; Mikula S
    Am J Rhinol; 2007; 21(4):428-32. PubMed ID: 17882911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
    Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
    J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
    Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
    Verbruggen K; Van Cauwenberge P; Bachert C
    Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.
    Sheinkopf LE; Rafi AW; Do LT; Katz RM; Klaustermeyer WB
    Allergy Asthma Proc; 2008; 29(5):530-7. PubMed ID: 18926061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of omalizumab in the treatment of nasal polyps.
    Vennera Mdel C; Picado C; Mullol J; Alobid I; Bernal-Sprekelsen M
    Thorax; 2011 Sep; 66(9):824-5. PubMed ID: 21109700
    [No Abstract]   [Full Text] [Related]  

  • 7. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis.
    Mostafa BE; Fadel M; Mohammed MA; Hamdi TAH; Askoura AM
    Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):121-128. PubMed ID: 31552526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
    D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin E to staphylococcal and streptococcal toxins in patients with chronic sinusitis/nasal polyposis.
    Tripathi A; Conley DB; Grammer LC; Ditto AM; Lowery MM; Seiberling KA; Yarnold PA; Zeifer B; Kern RC
    Laryngoscope; 2004 Oct; 114(10):1822-6. PubMed ID: 15454779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.
    Casale TB;
    Drugs Today (Barc); 2004 Apr; 40(4):367-76. PubMed ID: 15190389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis.
    Di Lorenzo G; Drago A; Esposito Pellitteri M; Candore G; Colombo A; Gervasi F; Pacor ML; Purello D'Ambrosio F; Caruso C
    Int Arch Allergy Immunol; 2001 Jun; 125(2):164-75. PubMed ID: 11435734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of omalizumab on nasal allergic inflammation.
    Plewako H; Arvidsson M; Petruson K; Oancea I; Holmberg K; Adelroth E; Gustafsson H; Sandström T; Rak S
    J Allergy Clin Immunol; 2002 Jul; 110(1):68-71. PubMed ID: 12110823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
    Rivero A; Liang J
    Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic sinusitis with nasal polyps: staphylococcal exotoxin immunoglobulin E and cellular inflammation.
    Conley DB; Tripathi A; Ditto AM; Reid K; Grammer LC; Kern RC
    Am J Rhinol; 2004; 18(5):273-8. PubMed ID: 15586797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
    van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA
    Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
    Ong YE; Menzies-Gow A; Barkans J; Benyahia F; Ou TT; Ying S; Kay AB
    J Allergy Clin Immunol; 2005 Sep; 116(3):558-64. PubMed ID: 16159624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.